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Abstract 
Background: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation that combines creatinine and cystatin C is superior to equations that include either 
measure alone in estimating glomerular filtration rate (GFR). However, whether cystatin C 
can provide any additional benefits in estimating GFR for Indigenous Australians, a 
population at high risk of end-stage kidney disease (ESKD) is unknown. 
Methods: Using a cross-sectional analysis from the eGFR Study of 654 Indigenous 
Australians at high risk of ESKD, eGFR was calculated using the CKD-EPI equations for 
serum creatinine (eGFRcr), cystatin C (eGFRcysC) and combined creatinine and cystatin C 
(eGFRcysC+cr). Reference GFR (mGFR) was determined using a non-isotopic iohexol 
plasma disappearance technique over 4 hours. Performance of each equation to mGFR was 
assessed by calculating bias, % bias, precision and accuracy for the total population, and 
according to age, sex, kidney disease, diabetes, obesity and c-reactive protein. 
Results: Data were available for 542 participants (38% men, mean [sd] age 45 [14] years). 
Bias was significantly greater for eGFRcysC (15.0 mL/min/1.73m2; 95%CI 13.3-16.4, 
p<0.001) and eGFRcysC+cr (10.3; 8.8-11.5, p<0.001) compared to eGFRcr (5.4; 3.0-7.2). 
Accuracy was lower for eGFRcysC (80.3%; 76.7-83.5, p <0.001) but not for eGFRcysC+cr 
(91.9; 89.3-94.0, p=0.29) compared to eGFRcr (90.0; 87.2-92.4). Precision was comparable 
for all equations. The performance of eGFRcysC deteriorated across increasing levels of c-
reactive protein. 
Conclusion: Cystatin C based eGFR equations may not perform well in populations with 
high levels of chronic inflammation. CKD-EPI eGFR based on serum creatinine remains the 
preferred equation in Indigenous Australians. 
Words: 248 (max 250) 
Keywords: CKD-EPI equation, creatinine, Cystatin C, GFR, Indigenous 
Short Summary (3-4 sentences pointing out the main message): 
Accurate estimation of renal function in Indigenous Australians is vital to identifying patients 
for clinical management as this population is at high risk of end-stage kidney disease. Our 
findings indicate that the CKD-EPI eGFR equation based on serum creatinine is the preferred 
equation in this population. Furthermore, cystatin C based eGFR may not be the optimum 
equation for estimating GFR in populations with a heavy burden of chronic inflammation. 
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1.0 Introduction 
Aboriginal and Torres Strait Islander Australians are the Indigenous people of Australia and 
experience disproportionately high rates of chronic kidney disease (CKD) compared to non-
Indigenous Australians. CKD leads to devastating health and social burdens as it progresses 
to end-stage kidney disease (ESKD), and is associated with high rates of cardiovascular 
disease, diabetes and premature mortality in this population [1]. Early detection of reduced 
kidney function is important, as early-stage kidney disease is often asymptomatic yet is 
associated with increased morbidity and mortality [2].  
Current international guidelines recommend the estimation of glomerular filtration rate 
(GFR) and measurement of urine albumin to creatinine ratio for the detection and assessment 
of CKD. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 
based on serum creatinine, age, gender and ethnicity is recommended and widely used in 
clinical practice [2]. However, serum creatinine-based eGFR may not be the optimal kidney 
filtration marker in some populations, as it can be affected by non-GFR factors, in particular, 
low muscle mass [3]. Cystatin C, a small molecular weight protein, is an alternative filtration 
marker that is also freely filtered through the glomerulus, with production less affected by 
muscle mass [4]. The CKD-EPI equation that combines both serum creatinine and cystatin C 
has been shown to be more accurate than equations that included either creatinine or cystatin 
C alone [5]. As such, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
recommend that eGFR based on creatinine and cystatin C be used as a confirmatory test in 
certain clinical situations where estimation of GFR with serum creatinine alone may be 
inaccurate [2].  
Indigenous Australians have a “linear” body build (narrow shoulders and hips, long limbs and 
short torso), which is proportionally associated with less muscle mass for a given weight [6, 
7]. Though previous analysis of our data supports the use of CKD-EPI based on creatinine in 
Indigenous Australian populations [8, 9], we have demonstrated that misclassification of 
GFR by creatinine based CKD-EPI eGFR was greatest at low weights (<72.5 kg) and that the 
inclusion of weight into the equation mitigated this difference. However, the strength of the 
association between the estimating equation based on serum creatinine and measured GFR 
was not substantially improved with the addition of other anthropometric measures, including 
fat free mass [10]. Equations combining cystatin C and creatinine perform well in multi-
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ethnic Asian populations also comprising individuals with relatively lower body mass indices 
[11], and in older adults with lower body mass indices [12].  
It is not known whether cystatin C can provide any benefits in estimating GFR for Indigenous 
Australians. Therefore, the aim of this study was to compare the performance of CKD-EPI 
eGFR equations based on serum creatinine (eGFRcr) to those based on either cystatin C 
(eGFRcysC) or a combination of cystatin C and creatinine (eGFRcysC+cr) in predicting 
reference GFR in Indigenous Australians. 
2.0 Materials and Methods 
2.1 Participants 
The methods have been described previously [13]. Participants were Aboriginal and/or Torres 
Strait Islander Australians, and men and women aged ≥16 years were recruited between 2007 
and 2011 from urban, rural and remote centres (within the Northern Territory, Queensland 
and Western Australia) across five pre-defined strata: (i) “healthy” people without diabetes, 
CKD or albuminuria, (ii) participants with diabetes or albuminuria and eGFR (MDRD-4) >90 
mL/min/1.73 m2; (iii) eGFR 60–90 mL/min/1.73 m2; (iv) eGFR30–59 mL/min/1.73 m2; (v) 
eGFR < 15–29 mL/min/1.73 m2. Participants with CKD and/or diabetes were recruited from 
participating medical services, and the “healthy” group were identified through community 
networks and staff of participating medical facilities. Individuals were not eligible if they 
were identified as having rapidly changing kidney function, receiving dialysis, pregnant or 
breastfeeding, or had an allergy or adverse reaction to iodine-based contrast media. At 
baseline, 654 Indigenous participants were recruited to the study. This analysis was based on 
542 participants. We excluded participants from this analysis if they were (i) acutely unwell 
(n=1); (ii) had a urinary tract infection (n=7); (iii) were aged <18 years (n=13), (iv) did not 
have an enzymatic creatinine measure (n=10), or (iv) did not have a cystatin C measure 
(n=81).  Compared to participants who were missing measurements for creatinine or cystatin 
C, participants who were included were younger (mean [sd] 45 [0.6] vs. 48 (1.6] years), less 
likely to be women (62 vs. 67%), less likely to have diabetes (38 vs. 48%) and 
macroalbuminuria (19 vs. 36%), but had similar mean BMI and blood pressure (data not 
shown). Participants provided informed consent, and the Human Research Ethics Committees 
of the joint Menzies School of Health Research—Northern Territory Department of Health 
Human Research Ethics Committee, including the Aboriginal subcommittee; Central 
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Australian Human Research Ethics Committee; Western Australian Aboriginal Health 
Information and Ethics Committee, Royal Perth Measurements Hospital Ethics Committee 
and Cairns and Hinterland Health Services District Human Research Ethics Committee 
approved the study. 
2.2 Measurements 
Participants underwent a health examination which included performance of the reference 
measure of GFR, collection of urine and non-fasting venous blood samples, anthropometric 
measurements and the administration of questionnaires [13]. Reference GFR was determined 
by measuring the renal clearance of non-isotopic iohexol (300 mg/mL, Omnipaque; GE 
Healthcare, Rydalmere, NSW, Australia) over 4 hours (with measurements at 120, 180 and 
240 minutes after the injection) using previously described methods [13]. Venous blood 
samples collected at 120 minutes after the injection were also used to measure serum 
creatinine and cystatin C. Venous blood samples were refrigerated, centrifuged within 4 hrs 
and aliquoted for transportation on ice prior to storage at –80 °C freezer. Iohexol was 
measured at a central laboratory (Austin Health, Melbourne Australia) using a validated 
HPLC assay modified from Niculescu-Duvaz et al. [14], and reference GFR (mL/min/1.73 
m2) was calculated [14, 15]. 
Serum creatinine and cystatin C were measured from thawed frozen sera by a single 
laboratory (Melbourne Pathology, Melbourne Australia). Serum creatinine was measured 
using a Roche IDMS- aligned enzymatic method (Roche Diagnostics, Australia) and cystatin 
C measured using an immunoturbidimetric assay standardised according to the IFCC (Roche 
Diagnostics, Australia) [16]. Cystatin C remains stable over several freeze-thaw cycles [17]. 
We calculated eGFR based on serum creatinine, cystatin C or a combination of both 
measures using the CKD-EPI equations [5]. 
Random urine samples were collected as part of standard clinical care to measure albumin 
and creatinine (to determine urine albumin to creatinine ratio) by local accredited pathology 
providers located at each of the recruitment sites using methods that have been previously 
reported [13]. Height was measured to the nearest 0.1 cm using a stadiometer on two 
occasions and a third measure was recorded if the first two measures differed by more than 
0.5cm. Weight to the nearest 0.1 kg was measured twice using digital scales and a third 
measure taken if the first two differed (Seca Model 767 and 841, Seca Deutschland, 
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Hamburg, Germany). Waist and hip circumferences were measured alternatively to the 
nearest 0.1 cm at least twice, and a third measure taken if the first two differed by more than 
1.0 cm. Waist circumference was measured at the midway point between the iliac crest and 
the costal margin, and hip circumference over the widest part of the buttocks. Fat free mass 
(FFM) was measured using single frequency bioimpedance (ImpediMed, USA) in a sub-
group of n=483.  
C-reactive protein (using high sensitivity assays) and haemoglobin A1c (HbA1c) were 
measured by local accredited pathology providers [13]. Diabetes was defined as a self-
reported diagnosis of Type 2 diabetes or HbA1c ≥6.5% [18]. Self-reported cigarette smoking 
status was also recorded as current, ex-smoker and never smoked. 
2.3 Statistical analysis 
Participant characteristics were described in terms of means (sd) or medians (inter-quartile 
range) for continuous variables, and numbers (proportions) for categorical variables, for the 
whole study population, and according to reference GFR groups: <60, 60-89 and ≥90 
mL/min/1.73m2). Performance of CKD-EPI equations based on serum creatinine (eGFRcr), 
cystatin C (eGFRcysC) and cystatin C plus serum creatinine (eGFRcysC+cr) to reference 
GFR were assessed for the whole study population, then according to sex, age groups (18-40, 
40-55 and ≥55 years), ethnicity (Aboriginal and/or Torres Strait Island), body mass index 
(BMI) based on World Health Organisation categories for Asian populations to account for 
the potentially different associations between BMI and risk of chronic conditions in this 
population (<23, 23-27.5 and ≥27.5 kg/m2 - the lowest categories were combined as there 
were too few participants with a BMI <18.5kg/m2) [19], waist circumference (<80cm women 
and <90 cm for men vs >80 cm women and >90 cm men), c-reactive protein (<3, 3-10 and 
>10 mg/l) sex, ethnic specific tertiles of % FFM and diabetes (diabetes vs no diabetes).  
We used metrics that have been previously reported for assessing equation performance [5, 
20, 21]. Bias was defined as the median difference (mL/min/1.73m2) between the reference 
GFR and the estimated GFR (i.e. mGFR– eGFR), and percentage bias as the median 
percentage difference relative to mGFR. Accuracy was defined as the percentage of eGFR 
values that fell within 30% of their corresponding mGFR value, and precision as the 
interquartile range of the absolute differences. Confidence intervals were calculated using the 
binomial exact method for proportions. We tested the difference between eGFR equations for 
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each of the performance measures using the Kruskal Wallis test to compare median absolute 
bias and median absolute percentage bias, quantile regression to compare precision and 
McNemar’s test to compare accuracy. In order to compare estimated values across categories 
of c-reactive protein we calculated p-values using the Mann-Whitney U-test for bias and % 
bias, interquantile range regression for precision and 2-test for accuracy. Individual 
differences between reference GFR and each of the eGFR equations were plotted, and 
quantile regression using the qreg command in Stata v14.1 was used to examine how bias 
varied as a (cubic) function of GFR. The function has been plotted across the whole range of 
eGFR. Analyses were conducted in Stata 14.1 (StataCorp, College Station, TX, USA). 
3.0 Results 
3.1 Participant characteristics 
Table 1 outlines the characteristics of the study population which comprised 542 (38% men) 
Indigenous Australians with a mean (sd) age of 45 (14) years. The majority of participants 
were Aboriginal (70%), 21% were Torres Strait Islander Australians and 9% were Aboriginal 
and Torres Strait Islander Australians. The median (IQR: inter-quartile range) of mGFR for 
the study population was 104 (83-122) mL/min/1.73m2, and 101 (81-114) mL/min/1.73m2 for 
eGFRcr, 89 (69-104) mL/min/1.73m2 for eGFRcysC, and 96 (76-108) mL/min/1.73m2 for 
eGFRcysC+cr. Decreasing mGFR (≥90, 60-89, <60 mL/min/1.73m2) was associated with 
older age, lower weight, greater HbA1c, slightly lower BMI, but larger waist circumference 
and waist to hip ratio, lower percent of FFM, and lower levels of c-reactive protein. 
Participants with lower mGFR were also less likely to be smokers, and more likely to have 
diabetes or albuminuria.  
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Table 1. Participant characteristics for the overall study population and according to 
reference GFR groups: the eGFR study. 
 All 
Participants 
mGFR < 60 
mL/min/1.73m2 
mGFR 60-89 
mL/min/1.72m2 
mGFR ≥90 
mL/min/1.73
m2 
 n=542 n=63 n=111 n=368 
Age (years) 45 (14) 59 (11) 53 (13) 39 (12) 
Men (%) 205 (38) 20 (32) 42 (38) 143 (39) 
Height (cm) 167 (8) 163 (7) 166 (8) 167 (8) 
Weight (kg) 83 (21) 78 (21) 81 (23) 85 (21) 
BMI (kg/m2) 30.0 (7.2) 29.1 (7.6) 29.2 (7.7) 30.4 (7.0) 
Percent Fat Free Mass 64.4 (9.3) 64.9 (9.3) 66.0 (9.6) 65.6 (9.5) 
C-reactive protein (mg/L) 5.8 (3-11) 5.0 (2.6-10) 5.2 (2.1-10) 6.0 (3-11) 
Waist (cm) 100 (16) 102 (16) 100 (17) 100 (16) 
Waist-hip ratio 0.94 (0.09) 0.98 (0.09) 0.94 (0.10) 0.93 (0.09) 
Current smoker (%) 226 (42) 15 (24) 33 (30) 178 (49) 
Diabetes (%) 216 (40) 42 (68) 52 (47) 122 (33) 
Haemoglobin A1c (mmol/L) 49.2 (19.0) 54.7 (18.2) 51.1 (21.0) 47.8 (18.4) 
Microalbuminuria (%)a 103 (20) 12 (20) 23 (23) 68 (19) 
Macroalbuminuria (%)a 98 (19) 41 (69) 25 (25) 32 (9) 
Enzymatic creatinine (nmol/L) 71 (57-87) 142 (103-194) 76 (67-94) 64 (54-77) 
Cystatin (mg/L) 0.92 (0.82-
1.10) 
1.95 (1.58-2.65) 1.11 (0.97-1.24) 0.87 (0.79-
0.95) 
CKD-EPI eGFRcr (mL/min/1.73m2) 101 (81-114) 39 (27-52) 81 (71-94) 109 (97-118) 
CKD-EPI eGFRcysC 
(mL/min/1.73m2) 
89 (69-104) 31 (20-41) 68 (58-79) 99 (87-109) 
CKD-EPI eGFRcysC+cr 
(mL/min/1.73m2) 
96 (76-108) 34 (23-44) 74 (63-85) 104 (94-113) 
Reference GFR (mL/min/1.73m2) 104 (83-122) 43 (27-53) 80 (72-86) 115 (103-127) 
Data are number (%) for categorical variables and mean (standard deviation) or median (inter-quartile range) for 
continuous variables.  
a Microalbuminuria 27-265 mg/g (3-30 mg/mmol); Macroalbuminuria > 265 mg/g (30mg/mmol). 
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFRcr: CKD-EPI estimated glomerular 
filtration rate equation based on serum creatinine; eGFRcysC: CKD-EPI estimated glomerular filtration rate 
equation based on cystatin C; eGFRcysC+cr: CKD-EPI estimated glomerular filtration rate equation based on 
cystatin C and serum creatinine; mGFR: Glomerular Filtration Rate measured using non-isotopic iohexol.  
3.2 Performance characteristics of eGFRcysC and eGFRcysC+cr compared to eGFRcr with 
reference to reference GFR 
The performance of CKD-EPI eGFR equations with reference to mGFR is presented in Table 
2. For the whole study population, bias was significantly greater for eGFRcysC 
(15.0mL/min/1.73m2; 95%CI 13.3-16.4, p<0.001) and eGFRcysC+cr (10.3; 8.8-11.5, 
p<0.001) compared to eGFRcr (5.4; 3.0-7.2). Accuracy was significantly lower for 
eGFRcysC (80.3%; 76.7-83.5, p <0.001) but not for eGFRcysC+cr (91.9; 89.3-94.0, p=0.29) 
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compared to eGFRcr (90.0; 87.2-92.4). Precision was comparable for all eGFR equations 
under examination.  
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Table 2. Performance characteristics of CKD-Epi eGFRcr, eGFRcysC and eGFRcysC+cr to reference GFR in Indigenous Australians, for the overall 
study populations and according to demographic and risk factor characteristics: the eGFR study. 
 n Bias % Bias Precision Accuracy 
  eGFRcr eGFRcysC eGFRcysC+cr eGFRcr eGFRcysC eGFRcysC+cr eGFRcr eGFRcysC eGFRcysC+cr eGFRcr eGFRcysC eGFRcysC+cr 
Total population 542 5.4 
(3.0-7.2) 
15.0 
(13.3-16.4)** 
10.3 
(8.8-11.5)** 
5.8 
(3.5-7.6) 
16.6 
(15.2-18.3)** 
11.5 
(9.9-13.0)** 
20.2 
(-5.0-15) 
21.0 
(5.7-26.7) 
18.0 
(1.8-19.8) 
90.0 
(87.2-92.4) 
80.3 
(76.7-83.5)** 
91.9 
(89.3-94.0) 
              
Men 205 8.4 
(6.5-11.4) 
14.9 
(12.2-16.6)** 
12.6 
(9.9-13.9)** 
8.4 
(7.0-11.0) 
15.5 
(12.9-18.5)** 
13.0  
(10.9-16.0)* 
19.9 
(-0.85-19.1) 
22.7 
(5.2-27.9) 
19.0 
(3.1-22.1) 
87.8 
(82.5-92.0) 
81.0 
(74.9-86.1) 
90.7 
(85.9-94.3) 
Women 337 2.5 
(0.2-5.4) 
15.2 
(13.2-16.9)** 
9.2 
(7.5-10.9)** 
2.7 
(0.2-5.7) 
17.0 
(15.6-19.2)** 
10.6 
(8.9-12.2)** 
20.1 
(-5.0 to 13.2) 
20.3 
(6.2-26.4) 
18.1 
(0.45-18.5) 
91.4 
(87.9-94.2) 
79.8 
(75.1-84.0)** 
92.6 
(89.2-95.1) 
              
Age 18-40 years 215 1.7 
(-1.1 to 4.5) 
11.7 
(9.9-15.0)** 
7.7 
(5.9-9.6)** 
1.5 
(-0.9 to 4.1) 
11.4 
(9.1-12.9)** 
6.8 
(5.1-9.0)** 
23.1 
(-7.9-15.1) 
22.4 
(2.3-24.8) 
21.0 
(-1.3 to 19.7) 
93.0 
(88.8-96.0) 
91.2 
(86.5-94.6) 
97.7 
(94.7-99.2)* 
Age 40-55 years 189 9.6 
(7.5-12.3) 
18.2 
(15.2-21.3)** 
14.1 
(11.6-16.3)** 
10.1 
(8.0-11.3)** 
19.9 
(16.9-21.8)** 
15.0 
(12.1-17.5)** 
19.1 
(-0.1 to 19.0) 
24.4 
(9.0-33.4) 
21.3 
(4.3-25.6) 
87.8 
(82.3-92.1) 
73.0 
(66.1-79.2)** 
87.8 
(82.3-92.1) 
Age ≥55 years 138 1.6 
(-0.6 to 5.2) 
14.7 
(12.5-17.0)** 
9.1 
(6.8-11.0)** 
2.9 
(-1.0 to 9.3) 
22.7 
(19.2-25.1)** 
14.0 
(11.6-16.8)** 
16.6 
(-4.5 to 12.1) 
16.2 
(7.2-23.4) 
11.7 
(3.9-15.7) 
88.4 
(81.9-93.2) 
73.2 
(65.0-80.4)** 
88.4 
(81.9-93.2) 
              
eGFRcr <60 
mL/min/1.73m2 
69 5.3 
(3.7-8.3) 
11.3 
(7.8-13.6)** 
9.9 
(7.4-11.0)* 
13.7 
(10.1-20.9) 
25.2 
(20.2-30.6)* 
22.8 
(18.2-27.1)* 
11.1 
(0.8-12.0) 
11.3 
(5.7-17.0) 
8.8 
(5.1-14.0) 
76.8 
(65.1-86.1) 
59.4 
(58.8-81.3) 
71.0 
(58.8-81.3)* 
eGFRcr 60-90 
mL/min/1.73m2  
114 8.3 
(3.7-12.6) 
13.1 
(10.7-16.1)* 
10.8 
(8.2-12.9) 
9.8 
(4.3-13.3) 
16.7 
(12.8-20.7)* 
12.8 
(10.0-15.3)* 
21.2 
(-3.1 to 18.1) 
18.3 
(4.1-22.4) 
15.3 
(3.8-19.1)* 
85.1 
(77.2-91.1) 
83.3 
(75.2-89.7) 
94.2 
(91.2-96.3) 
eGFRcr ≥90 
mL/min/1.73m2  
359 3.2 
(1.6-6.6) 
12.4 
(10.4-15.3)** 
9.4 
(7.4-12.2)** 
3.0 
(1.4-5.8) 
11.0 
(9.3-12.6)** 
8.1 
(6.6-9.9)** 
21.6 
(-6.3 to 15.2) 
24.3 
(6.1-30.5) 
21.6 
(0.40-22.0) 
94.2 
(91.2-96.3) 
83.3 
(79.0-87.0)** 
96.4 
(93.9-98.1) 
              
BMI <23 kg/m2 67 -5.8 
(-7.9 to -
2.0) 
6.01 
(3.4-9.3)* 
1.2 
(-2.0 to 4.7) 
-6.6 
(-9.5 to -3.2) 
7.0 
(4.1-11.5) 
1.4 
(-2.4 to 4.9) 
17.2 
(-14.1 to 3.0) 
15.9 
(-2.8 to 
13.1) 
13.0 
(-6.3 to 6.7) 
85.1 
(74.3-92.6) 
94.0 
(85.4-98.3) 
97.0 
(89.6-99.6)* 
BMI 23-27.5 
kg/m2 
106 6.5 
(1.4-8.5) 
13.7 
(10.6-16.0)** 
9.6 
(7.1-11.3)* 
6.8 
(1.7-9.2) 
14.2 
(11.0-17.2)** 
9.5 
(7.6-13.5)* 
16.0 
(-3.2 to 12.8) 
15.6 
(5.2-20.8) 
14.8 
(1.9-16.6) 
89.6 
(82.2-94.7) 
83.0 
(74.5-89.6) 
87.7 
(79.9-93.3) 
BMI ≥27.5 kg/m2 205 8.3 
(5.4-9.5) 
22.4 
 (17.3-
26.2)** 
14.8 
(13.1-17.2)** 
7.9 
(5.5-10.0) 
23.6 
(20.8-25.8) 
16.0 
(13.9-17.6)** 
21.4 
(-2.8 to 
18.7)** 
23.4 
(11.1-34.5) 
18.9 
(6.6-25.5) 
89.8 
(84.8-93.5) 
69.8 
(63.0-76.0)** 
89.8 
(84.8-93.5) 
              
No diabetes 325 3.6 
(1.5-6.9) 
12.6 
(10.6-14.8) 
8.2 
(7.0-10.1) 
3.5 
(1.5-7.0) 
12.8 
(11.0-14.0) 
8.2 
(7.0-10.0) 
20.3 
(-5.9 to 14.4) 
20.3 
(2.4-22.8) 
17.0 
(0.07-17.1) 
92.6 
(89.2-95.2) 
89.8 
(86.0-92.9) 
96.0 
(93.3-97.9) 
Diabetes 216 7.0 
(4.8-8.6) 
18.3 
(16.2-22.2) 
13.1 
(11.1-16.5) 
8.2 
(5.2-11.2) 
23.4 
(21.3-25.9) 
16.6 
(13.9-19.3) 
22.5 
(-3.0 to 19.5) 
22.2 
 (9.8-32.0) 
20.2 
(5.1-25.3) 
86.6 
(81.2-90.8) 
66.3 
(59.5-72.5) 
86.1 
(80.8-90.4) 
P values were calculated to compare eGFR equations based on cystatin C to eGFR based on serum creatinine;* p <0.05; ** p <0.001 
Bias and % Bias are median (95% CI); Precision is interquartile range of the bias (25th, 75th percentile of the bias); Accuracy is % of eGFR within 30% of reference GFR (95% CI).  
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFRcr: CKD-EPI estimated glomerular filtration rate equation based on serum creatinine; eGFRcysC: CKD-EPI estimated glomerular filtration 
rate equation based on cystatin C; eGFRcysC+cr: CKD-EPI estimated glomerular filtration rate equation based on cystatin C and serum creatinine. 
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Figure 1 plots each of the eGFR equations in units of mL/min/1.73m2 according to the 
individual differences between mGFR and eGFRcr (A), eGFRcysC (B) and eGFRcysC+cr 
(C), respectively, and shows that while all measures tended to underestimate mGFR, a greater 
proportion of eGFRcr and eGFRcysC+cr values fell within 30% of mGFR values compared 
to eGFRcysC. Underestimation of mGFR by eGFRcysC occurred across the range of 
eGFRcysC measures (Table 2 and Figure 1). 
Figure 1. Performance of eGFRcr (A), eGFRcysC (B) and eGFRcysC+cr (C) to estimate 
reference GFR. Reference GFR (mGFR) minus the relevant eGFR is plotted against 
eGFR (values above zero indicate a negative bias for eGFR). 
 
Figure note: Data inside the wedge are ‘accurate’ (i.e. within 30% of measured GFR). The 
thick lines shows the modelled (see Methods) bias.
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Table 2 shows that the performance of cystatin C eGFR equations were similar for men and 
women, and for those aged 40-55 years and ≥55 years. Similar trends were observed for 
different Indigenous Australian populations (i.e. comparing Aboriginal to Torres Strait 
Islander Australians) (data not shown). For younger individuals aged 18-40 years, cystatin 
based eGFR equations did not provide any benefit in terms of bias, but eGFRcysC+cr (97.7: 
94.7-99.2, p=0.02) provided significantly greater accuracy compared to eGFRcr (93.0; 88.8-
96.0). There was no improvement in performance of cystatin C based eGFR equations among 
those with diabetes (Table 2).  
When we examined the performance of eGFR equations in estimating reference GFR 
according to groups of adiposity, eGFRcysC and eGFRcysC+cr did not provide any benefits 
in terms of bias, precision or accuracy when compared to eGFRcr for individuals with a BMI 
≥23kg/m2 (Table 2) or waist circumference ≥80cm for women or ≥90cm for men (data not 
shown). Whilst we did observe some improvements in estimation of mGFR for eGFR 
equations based on cystatin C compared to eGFRcr for those with BMI <23 kg/m2, findings 
were not consistent for all performance measures (Table 2). Furthermore, we did not observe 
the same improvements in estimation of mGFR for cystatin C equations compared to eGFRcr 
when adiposity was estimated using %FFM (data not shown).  
When the cohort was stratified by c-reactive protein (<3, 3-10 and >10 mg/L) we found that 
whilst there was no significant differences in bias, % bias or accuracy for eGFRcr across 
increasing c-reactive protein groups, bias and % bias significantly increased with increasing 
c-reactive protein for eGFRcysC and eGFRcysC+cr. Accuracy for estimating mGFR also 
significantly deteriorated for eGFRcysC with increasing c-reactive protein (Table 3).
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Table 3. Comparison of performance characteristics of eGFRcr, eGFRcysC and 
eGFRcr+cysC to reference GFR according to increasing c-reactive protein: the eGFR 
study 
Estimating equation  ≤3 mg/L 3-10 mg/L >10 mg/L P-
value 
n  164 219 139  
eGFRcr 
(mL/min/1.73m2) 
Bias 4.8 (1.7-8.7) 7.0 (2.6-9.1) 5.2 (2.1-7.9) 0.78 
 % bias 6.1 (1.5-9.9) 6.6 (2.9-9.5) 5.9 (2.8-8.0) 0.89 
 Precision 19.7 (-4.5 to 15.1) 22.9 (-5.0 to 17.9) 19.7 (-5.1 to 14.6) 0.88 
 Accuracy 90.2 (84.6-94.3) 89.0 (84.1-92.9) 89.9 (83.7-94.4) 0.92 
 % ≤30 3 5 3  
 % >30% 7 6 7  
      
eGFRcysC 
(mL/min/1.73m2) 
Bias 13.0 (11.0-15.1) 14.9 (12.4-17.4) 20.1 (16.1-24.9) <0.001 
 % bias 13.4 (11.7-16.2) 16.3 (13.1-19.4) 22.0 (18.1-26.0) <0.001 
 Precision 17.0 (4.1-21.0) 22.1 (4.8-26.9) 22.7 (9.4-32.0) 0.14 
 Accuracy 82.9 (76.3-88.3) 82.2 (74.5-87.0) 71.9 (63.74-79.2) 0.029 
 % ≤30 1 0 0  
 % >30% 16 17 28  
      
eGFRcysC+cr 
(mL/min/1.73m2) 
Bias 8.6 (6.5-10.7) 9.7 (7.6-12.6) 13.3 (11.0-15.4) 0.015 
 % bias 9.2 (7.1-12.2) 11.5 (8.8-13.3) 15.1 (12.5-16.6) 0.017 
 Precision 16.8 (1.0-17.8) 19.8 (1.0-20.8) 17.9 (5.6-23.5) 0.77 
 Accuracy 93.9 (89.1-97.0) 91.3 (86.8-94.7) 89.9 (83.6-94.4) 0.43 
 % ≤30 1 0 0  
 % >30% 5 8 10  
Bias and % Bias are median (95% CI); Precision is interquartile range of the bias (25th, 75th percentile of the 
bias); Accuracy is % of eGFR within 30% of reference GFR (95% CI).  
P-values were calculated using the Mann–Whitney U-test for bias and% bias, interquantile range regression for 
precision, 2-test for accuracy. 
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFRcr: CKD-EPI estimated glomerular 
filtration rate equation based on serum creatinine; eGFRcysC: CKD-EPI estimated glomerular filtration rate 
equation based on cystatin C; eGFRcysC+cr: CKD-EPI estimated glomerular filtration rate equation based on 
cystatin C and serum creatinine 
 
4.0 Discussion 
This is the first study to assess the performance of cystatin C based eGFR CKD-EPI 
equations in Indigenous Australians, and provides important information on the application of 
eGFR equations in the detection and management of CKD in a population at high risk of 
ESKD. Our study of Indigenous Australians who were recruited from more than 20 sites in 
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urban, rural and remote regions of Australia shows that CKD-EPI eGFR equations that 
include cystatin C, either in isolation or in combination with serum creatinine, do not provide 
any overall benefits beyond CKD-EPI eGFR based on serum creatinine in estimating mGFR. 
These findings were observed across a range of demographic and clinical characteristics. 
Although there was some indication that the combined cystatin C-creatinine eGFR equation 
performed better than eGFRcr among those aged younger than 40 years and those with a 
leaner body composition, results were not consistent for all performance measures. 
In our total study population, estimating equations based on cystatin C compared to those 
based on creatinine demonstrated significantly greater absolute and percentage bias, and no 
improvements in precision or accuracy were observed. These findings are in contrast to those 
recently reported from a large meta-analysis of predominantly Europid populations. The 
CKD-EPI consortium meta-analysis showed little difference between estimating equations 
based on creatinine, cystatin C or both in terms of bias, but significant improvements in both 
precision and accuracy were reported for equations based on cystatin C compared to 
equations based on creatinine alone [5]. However, the CKD-EPI equation based on cystatin C 
may not perform as well in other populations [22], and differences in population 
characteristics of our study population to those included in the CKD-EPI consortium analysis 
may explain these disparate results.  
Our study population was characterised by relatively high levels of obesity, diabetes and 
smoking, conditions associated with inflammatory responses [23, 24]. Physiological 
processes unrelated to glomerular function affect both serum creatinine and cystatin C. 
Higher creatinine values have been associated with greater muscle mass and diets high in 
meat, and whilst cystatin C is less affected by these factors, other conditions associated with 
inflammation, including diabetes [25], smoking [26] and use of immunosuppressants [27], 
may affect cystatin C concentrations. C-reactive protein, a marker of inflammation, has been 
associated with higher values of cystatin C [25]. Obesity was highly prevalent in our study 
population, and few participants were lean. We found that the performance of eGFR based on 
cystatin C in estimating mGFR deteriorated with greater BMI and larger waist circumference. 
In addition, there were no significant differences for bias, accuracy or precision for eGFRcr 
in estimating mGFR across levels of c-reactive protein, performance estimates for cystatin C 
deteriorated with increasing c-reactive protein. It is therefore possible that the determinants of 
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cystatin C levels in this Indigenous Australian population were influenced by factors 
associated with chronic inflammation. 
Our findings of cystatin C based equations being influenced by obesity are supported by other 
studies [28] including Asian and Indigenous populations [29-31]. One observational study of 
immigrant South Asians was also able to demonstrate that the relationship between increasing 
adiposity and eGFRcysC was largely explained by factors related with chronic inflammation, 
including c-reactive protein [30]. In another study of Indigenous youth, cystatin C was 
strongly associated with the metabolic syndrome [31]. In contrast to our findings, however, 
other studies of Asian populations have reported that the combined eGFRcysC+cr equation 
was superior to eGFRcr [11, 32, 33]. The authors from the study of a multiethnic Asian 
population postulated that in that population of individuals from diverse Asian heritages, the 
estimation of mGFR was improved because markers of both fat and muscle, as represented 
by cystatin C and creatinine, respectively, were included [11]. Therefore, the relative impact 
of these opposing physiologies may need to be taken into account when assessing the 
appropriateness of GFR estimating equations in different ethnic populations. 
The eGFR study is the largest study to investigate the performance of cystatin C based eGFR 
in estimating mGFR in Indigenous Australians. These findings may be generalisable to 
Indigenous Australians living in urban, rural and remote locations, as well as those with and 
without diabetes and kidney disease. Nevertheless, limitations exist. Firstly, the 
representativeness of the study population is unknown, as participants were volunteers and 
not randomly selected. Secondly, serum cystatin C can also be affected by thyroid function 
and corticosteroids, but we were not able to ascertain the influence of these factors. Thirdly, 
the renal measures and mGFR were only taken once, and given that measurement error is 
reported to be 5-20%, excess variability in measurements may have attenuated our study 
findings. 
The results of our study indicate that compared to CKD-EPI eGFR based on serum 
creatinine, cystatin C based eGFR equations demonstrated poorer performance in estimating 
mGFR. Nevertheless, eGFR equations based on cystatin C may demonstrate a different 
relationship with renal and cardiovascular disease, and overall mortality outcomes. A recent 
meta-analysis revealed that compared to eGFRcr, cystatin C based eGFR equations were 
more strongly associated with cardiovascular disease, all-cause mortality and ESKD [34]. 
These findings that are based predominantly on North American and European populations 
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have also been observed in other ethnicities that are at high risk for kidney disease including 
older Mexican Americans [35] and Pima Indians with type 2 diabetes from the United States 
[36]. Given the high prevalence of conditions and behaviours associated with elevated 
chronic inflammation observed in our population of Indigenous Australians, further analysis 
of the role of cystatin C in predicting renal and mortality outcomes should also be assessed.  
5.0 Conclusions 
In conclusion, accurate estimation of renal function in Indigenous Australians is vital to 
identifying patients for clinical management. Our findings indicate that the addition of serum 
cystatin C either in isolation or together with serum creatinine does not improve the 
performance of eGFR equations in estimating GFR in Indigenous Australians. Therefore, we 
support the continued use of CKD-EPI eGFR equations based on serum creatinine in 
Aboriginal and Torres Strait Islander Australians and do not support the use of cystatin C 
based equations for further analysis of specific subgroups. 
6.0 Abbreviations 
BMI Body mass index 
CKD Chronic kidney disease 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
eGFR Estimated glomerular filtration rate 
eGFRcr Estimated glomerular filtration rate calculated using the CKD-EPI equation 
for serum creatinine 
eGFRcysC+cr Estimated glomerular filtration rate calculated using the CKD-EPI equation 
for cystatin C and serum creatinine 
eGFRcystC Estimated glomerular filtration rate calculated using the CKD-EPI equation 
for cystatin C 
ESKD End-stage kidney disease 
FFM Fat free mass 
GFR Glomerular filtration rate 
HbA1c Haemoglobin A1c 
KDIGO Kidney Disease Improving Global Outcomes 
mGFR Reference glomerular filtration rate determined using non-isotopic iohexol 
plasma disappearance technique over 4 hours 
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